BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on ...

The biotech’s phase 3 delivered the hoped-for second biomarker hit, reporting an 82% decline in serum creatine kinase after ...

BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial, ...

Analysts estimate that BridgeBio Pharma will report an earnings per share (EPS) of $-0.82. The announcement from BridgeBio ...

BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest ...

New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that ...

The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle ...

All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile ...

BridgeBio Pharma Inc.’s drug to treat a devastating muscle-wasting disorder met its goal in a late-stage trial, paving the ...

H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $80 from $70 and keeps a Buy rating on the shares. The firm now includes ...

BridgeBio said an experimental therapy for a rare form of muscular dystrophy succeeded in a key trial, potentially setting up ...

BridgeBio Pharma shares surge on positive BBP-418 trial results for limb-girdle muscular dystrophy. Read more here.